5-chloro-N-isopropyl-2-nitro-aniline | 101167-01-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-chloro-N-isopropyl-2-nitro-aniline
• 英文别名: 5-Chlor-N-isopropyl-2-nitro-anilin；Benzenamine, 5-chloro-N-(1-methylethyl)-2-nitro-；5-chloro-2-nitro-N-propan-2-ylaniline
• CAS: 101167-01-5
• 化学式: C₉H₁₁ClN₂O₂
• 分子量: 214.652
• InChiKey: RWVJQUQJUJYZOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-chloro-N-isopropyl-2-nitro-aniline 在 palladium on activated charcoal potassium tert-butylate 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 45.25h， 生成 (6-Chloro-3-oxo-4-propan-2-ylquinoxalin-2-yl) diethyl phosphate
  参考文献：
  名称：

  3-Phenyl-Substituted Imidazo[1,5-a]quinoxalin-4-ones and Imidazo[1,5-a]quinoxaline Ureas That Have High Affinity at the GABA_A/Benzodiazepine Receptor Complex

  摘要：

  A series of imidazo[1,5-alpha]quinoxalin-4-ones and imidazo[1,5-alpha]quinoxaline ureas containing substituted phenyl groups at the 3-position was developed. Compounds within the imidazo-[1,5-alpha]quinoxaline urea series had high affinity for the GABA(A)/benzodiazepine receptor complex with varying in vitro efficacy, although most analogs were partial agonists as indicated by [S-35]TBPS and Cl- current ratios. Interestingly, a subseries of piperazine ureas was identified which had biphasic efficacy, becoming more antagonistic with increasing concentration. Analogs within the imidazo [1,5-alpha] quinoxalin-4-one series had substantially decreased binding affinity as compared to the quinoxaline urea series. These compounds ranged from antagonists to full agonists by in. vitro analysis, with several derivatives having roughly 4-fold greater intrinsic activity than diazepam as indicated by Cl- current measurement. Numerous compounds from both series were effective in antagonizing metrazole-induced seizures, consistent with anti-convulsant properties and possible anxiolytic activity. Most of the quinoxaline ureas and quinoxalin-4-ones were active in an acute electroshock physical dependence side effect assay in mice precluding further development.

  DOI：

  10.1021/jm960070+
• 作为产物：
  描述：

  3,4-二硝基氯苯 、 异丙胺 生成 5-chloro-N-isopropyl-2-nitro-aniline
  参考文献：
  名称：

  Feitelson et al., Journal of the Chemical Society, 1952, p. 2389,2393

  摘要：

  DOI：

文献信息

• [EN] BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY<br/>[FR] COMPOSES DE BENZIMIDAZOLONE A ACTIVITE D'AGONISTES DU RECEPTEUR 5-HT4
  申请人：PFIZER JAPAN INC

  公开号：WO2005021539A1

  公开（公告）日：2005-03-10

  This invention provides a compound of the formula (I) or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

  该发明提供了式(I)的化合物或其药用可接受的盐，以及含有这种化合物的组合物和利用这种化合物制造用于治疗胃食管反流病、胃肠疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征（IBS）、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病、心力衰竭、心律失常、糖尿病和呼吸暂停综合征的药物的用途。这些化合物具有5-HT4受体激动活性，因此对于治疗哺乳动物，尤其是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等疾病是有用的。
• Benzimidazolone compounds having 5-HT4 receptor agonistic activity
  申请人：Katsu Yasuhiro

  公开号：US20050148573A1

  公开（公告）日：2005-07-07

  This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HT 4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

  本发明提供了一种式（I）的化合物或其药学上可接受的盐，并且还提供了包含这种化合物的组合物以及使用这种化合物制造治疗胃食管反流病、胃肠道疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征（IBS）、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病、心力衰竭、心律失常、糖尿病和呼吸暂停综合征的药物的用途。这些化合物具有5-HT4受体激动作用，因此对于哺乳动物，特别是人类的治疗胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等非常有用。
• Benzimidazole compounds
  申请人：G. D. Searle & Co.

  公开号：US05521193A1

  公开（公告）日：1996-05-28

  This invention relates to compounds useful in treating HT.sub.4 and/or HT.sub.3 mediated, conditions of the formula ##STR1## or a pharmaceutically acceptable salt thereof.

  本发明涉及一种用于治疗HT.sub.4和/或HT.sub.3介导的条件的化合物，其化学式为##STR1##或其药学上可接受的盐。
• Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity
  申请人：Katsu Yasuhiro

  公开号：US20100273794A1

  公开（公告）日：2010-10-28

  This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HT 4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

  本发明提供了公式（I）的化合物或其药学上可接受的盐，以及含有这样的化合物的组合物和使用这样的化合物制造治疗胃食管反流病、胃肠道疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征（IBS）、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病、心力衰竭、心律失常、糖尿病和呼吸暂停综合症的药物。这些化合物具有5-HT4受体激动活性，因此对哺乳动物，特别是人类的治疗胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等非常有用。
• Design, Synthesis, and Evaluation of New 1<i>H</i>-Benzo[<i>d</i>]imidazole Based PqsR Inhibitors as Adjuvant Therapy for <i>Pseudomonas aeruginosa</i> Infections
  作者：Fadi Soukarieh、Alaa Mashabi、William Richardson、Eduard Vico Oton、Manuel Romero、Jean-Frédéric Dubern、Shaun N. Robertson、Simone Lucanto、Zoe Markham-Lee、Tomás Sou、Irena Kukavica-Ibrulj、Roger C. Levesque、Christel A. S. Bergstrom、Nigel Halliday、Barrie Kellam、Jonas Emsley、Stephan Heeb、Paul Williams、Michael J. Stocks、Miguel Cámara

  DOI：10.1021/acs.jmedchem.3c00973

  日期：2024.1.25

  one of three QS systems in P. aeruginosa, results in reduction of bacterial virulence gene expression and biofilm maturation. Herein, we report a hit to lead process to fine-tune the potency of our previously reported inhibitor 1 (IC50 3.2 μM in P. aeruginosa PAO1-L), which led to the discovery of 2-(4-(3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl)amino)-2-hydroxypropoxy)phenyl)acetonitrile (6f)

  根据世界卫生组织 （WHO） 的说法，铜绿假单胞菌是需要立即关注的首要病原体之一。由于新型抗菌剂的严重短缺，靶向群体感应 （QS），一种控制毒力的细菌细胞间信号系统，已成为一种很有前途的抗生素辅助治疗方法。对 pqs 系统（铜绿假单胞菌的三个 QS 系统之一）的干扰导致细菌毒力基因表达降低和生物膜成熟。在此，我们报告了一个微调我们之前报道的抑制剂 1 效力（铜绿假单胞菌 PAO1-L 中的 IC50 3.2 μM）的命中到领先过程，这导致发现 2-（4-（3-（（6-氯-1-异丙基-1H-苯并[d]咪唑-2-基）氨基）-2-羟丙氧基）苯基）乙腈 （6f） 作为有效的 PqsR 拮抗剂。化合物 6f 在低亚微摩尔浓度下抑制铜绿假单胞菌中 PqsR 控制的 PpqsA-lux 转录报告基因融合。此外，6f 对铜绿假单胞菌 CF 分离株的疗效提高，显著抑制绿脓菌素、2-烷基-4（1H）-喹诺酮类药物的产生。